Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects - non-smoking, male and female volunteers 18-65 years of age weighing at least 60kg with BMI between 18- 40kg/m2. Females of childbearing potential sexually inactive or using acceptable birth control method for 14 days prior to through 3 days following dosing or postmenopausal with amenorrhea for at least 2 years, adequate venous access~* Healthy subjects - medically healthy based on designated clinical criteria including CLcr\>80 ml/min and hemoglobin 11g/dL or greater~* Renally-impaired subjects - medically acceptable based on designated clinical criteria including good glucose control if diabetic, CLcr 30 to 80 ml/min, hemoglobin 10 g/dL or greater, anticipation that medications necessary for treatment of renal disease and/or other coexisting disease will remain stable for 14 days prior to and throughout the study period~Exclusion Criteria:~* Pregnant or lactating; history of presence of significant cardiovascular, pulmonary, hepatic, hematologic, gastrointestinal, endocrine, immunologic, musculoskeletal, dermatologic, neurologic, or psychiatric disease; positive at screening for HIV, HbsAg, or HCV; QTc \>440 msec (male) or 450 msec (female) or PR \>200 msec, sitting BP \< 90/55, sitting radial pulse \< 45 bpm at screening or baseline; history of G6PD deficiency, myasthenia gravis, or optic neuritis; hypersensitivity or idiosyncratic reaction to mefloquine or quinidine; recent/ongoing use of drugs or substances known to inhibit or induce CYP P450 enzymes and/or P-glycoprotein or quinine; hx of alcoholism or drug abuse within previous 2 years; donation of blood or plasma within 56 days prior to dosing; receipt of study medication in another clinical trial within 30 days of dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): quinine sulfate 648mg in subjects with normal renal function (CLcr \> 80mL/min)
- 2 (Type: EXPERIMENTAL): quinine sulfate 648mg in subjects with mildly impaired renal function (CLcr \> 50 to 80 mL/min)
- 3 (Type: EXPERIMENTAL): quinine sulfate 648mg in subjects with moderately impaired renal function (CLcr 30 to 50mL/min)

Based on this trial design, predict the completion outcome and termination type (if applicable).